2025
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Cummings J, Atri A, Feldman H, Hansson O, Sano M, Knop F, Johannsen P, León T, Scheltens P. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimer's Research & Therapy 2025, 17: 14. PMID: 39780249, PMCID: PMC11708093, DOI: 10.1186/s13195-024-01666-7.Peer-Reviewed Original ResearchConceptsSymptomatic ADAlzheimer's diseaseDouble-blindGlucagon-like peptide-1 receptor agonist semaglutidePlacebo-controlled phase 3 trialOnce-daily oral semaglutideClinical Dementia RatingMild cognitive impairmentAD-related processesAD biomarkersSafety of semaglutideDose-escalation regimenPhase 3 studyBaseline to weekEffect of semaglutidePhase 3 trialCognitive impairmentPathophysiology of Alzheimer's diseasePotential disease-modifying effectsDementia RatingSymptomatic Alzheimer's diseaseTreatment of type 2 diabetesPlacebo-controlledType 2 diabetesDisease-modifying potential
2024
Comparison of eligibility criteria and baseline characteristics between the patient populations of evoke and evoke+, Clarity AD, and TRAILBLAZER‐ALZ‐2
Feldman H, Scheltens P, Hansson O, Sano M, van der Flier W, Bardtrum L, Johannsen P, Jeppesen R, Leon T, Hansen C, Cummings J. Comparison of eligibility criteria and baseline characteristics between the patient populations of evoke and evoke+, Clarity AD, and TRAILBLAZER‐ALZ‐2. Alzheimer's & Dementia 2024, 20: e083684. PMCID: PMC11713343, DOI: 10.1002/alz.083684.Peer-Reviewed Original ResearchClinical Dementia RatingNon-white participantsPositron emission tomographyEarly-stage AD patientsAlzheimer's diseaseMini-Mental State ExaminationMild AD dementiaMild cognitive impairmentTau positron emission tomographyEpisodic memoryGlucagon-like peptide-1 receptor agonist semaglutidePlacebo-controlled trialInclusion criteriaTau pathologyCDR sumCognitive impairmentMini-MentalState ExaminationDementia RatingImpaired patientsAD patientsGlobal scoreAmyloid positivityTrial populationDisease-modifying therapies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply